X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

PSYCHOPHARMACOLOGY

期刊標題檢索 PSYCHOPHARMACOL 最新評論: Submission deadline by the end of December 2022; Notification for ma... (2024-03-06)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[PSYCHOPHARMACOLOGY]您好,您是該頁面的第 30935 位訪客。

期刊簡介
期刊名稱PSYCHOPHARMACOLOGY PSYCHOPHARMACOLOGY
LetPub Score
6.7
50 ratings
Rate

Reputation
7.6

Influence
5.5

Speed
9.3

期刊簡稱PSYCHOPHARMACOLOGY
ISSN0033-3158
E-ISSN1432-2072
h-index181
CiteScore
CiteScoreSJRSNIPCiteScore Rank
7.101.0530.861
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmacology
Q288 / 313

自引率 (2023-2024)2.90%自引率趨勢
掲載範囲
Official Journal of the European Behavioural Pharmacology Society (EBPS)

Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

Human Psychopharmacology: Experimental

This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

Human Psychopharmacology: Clinical and Translational

This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

Preclinical psychopharmacology: Behavioral and Neural

This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

Preclinical Psychopharmacology: Translational

This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
官方網站https://www.springer.com/213
在線稿件提交https://www.editorialmanager.com/psph/
開放訪問No
出版商Springer Berlin Heidelberg
主題領域医学
出版國/地區GERMANY
發行頻率月2回刊行
創刊年1959
每年文章數201每年文章數趨勢
黃金OA百分比29.69%
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
NEUROSCIENCESSCIEQ2109/310
PHARMACOLOGY & PHARMACYSCIEQ2100/354
PSYCHIATRYSCIEQ275/276
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0033-3158%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Fast, 2-4 Week(s)
競爭力 *來自作者的數據: Difficult
參考鏈接
相關期刊 【PSYCHOPHARMACOLOGY】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    World PsychiatryH-index: 70

    CiteScore: 64.10
    PSYCHOTHERAPY AND PSYCHOSOMATICSH-index: 86

    CiteScore: 29.40
    AMERICAN JOURNAL OF PSYCHIATRYH-index: 325

    CiteScore: 22.30
    Biological PsychiatryH-index: 290

    CiteScore: 18.80
    MOLECULAR PSYCHIATRYH-index: 196

    CiteScore: 20.50
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRYH-index: 222

    CiteScore: 21.00
    BRITISH JOURNAL OF PSYCHIATRYH-index: 209

    CiteScore: 13.70
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYH-index: 188

    CiteScore: 15.70
    CURRENT OPINION IN PSYCHIATRYH-index: 80

    CiteScore: 12.20
    CNS DRUGSH-index: 100

    CiteScore: 12.00
    學科內最受檢索的期刊 頁面查看次數
    JOURNAL OF AFFECTIVE DISORDERS154042
    MOLECULAR PSYCHIATRY83513
    PSYCHIATRY RESEARCH69350
    Biological Psychiatry68606
    NEUROPSYCHOPHARMACOLOGY63100
    BMC Psychiatry59676
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY48075
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY46094
    JOURNAL OF PSYCHIATRIC RESEARCH45739
    PSYCHOLOGICAL MEDICINE43406
  •  

    PSYCHOPHARMACOLOGY PSYCHOPHARMACOLOGY
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [PSYCHOPHARMACOLOGY] 的評論撰寫評論
作者: 帅子


領域: 医学
審稿時間: 3.0 month(s)
結果: 修改後接受


撰寫評論

2024-03-06 13:47:21 評論於
Submission deadline by the end of December 2022;
Notification for major revisions by the end of March 2023;
Revision deadline by the end of April 2023;
Direct acceptance notification by the end of May 2023.
Comment from Expert 1: All issues have been resolved, thank you;
Comment from Expert 2: Successfully resolved all issues, great job!
(0) 讚! | 帅子

作者: 留云济深


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-05 21:24:34 評論於
Do you need to provide original data?
(0) 讚! | 留云济深

作者: weibos


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2023-10-30 13:15:54 評論於
Two months for major revisions. The processing speed and editing response speed are relatively fast. The journal is quite well-known in the industry. The difficulty is not small. You can try submitting some innovative articles. Overall, it is a very good veteran journal
(0) 讚! | weibos

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 10:24:19 評論於
When explaining your innovative points, it is important to focus on describing the shortcomings of past research, and clearly and comprehensively explain your solution ideas. Innovation requires the use of introduction techniques, so it is beneficial to write more content that is advantageous to yourself. In order to highlight the innovation of this research, it is necessary to select from numerous citations the aspects of the research that highlight its differences and characteristics. For example: (1) timing issues; (2) research methodology issues; (3) research area issues; (4) uncertainty; (5) propose your own hypothesis for verification
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 09:29:06 評論於
There is usually no word limit, but it should be proportional
(0) 讚! | 维尔娜菲茨杰拉德

作者: Darlene Pepys


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 21:57:24 評論於
Introduction, how many words is usually written?
(0) 讚! | Darlene Pepys

作者: 平原文波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 17:11:23 評論於
How is the innovation of the article reflected in the introduction?
(0) 讚! | 平原文波

作者: 巴蜀孤容


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-02-20 15:48:20 評論於
Is there a layout fee, and how much is it?
(0) 讚! | 巴蜀孤容

作者: 东京冰可


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-12-30 15:27:43 評論於
Review speed: 3.0 | Submission acceptance rate: 50.0
Research focus: Psychopharmacology; Basic experimental experience sharing: Submitted twice, both accepted. The first submission was slower, submitted in mid-December, returned for revision in February of the following year, accepted in early April, online at the end of June, and published in August. The second submission was faster, submitted at the end of July, returned for revision in September, accepted in early October, online at the end of October, and published in January of the following year
(0) 讚! | 东京冰可

作者: 韦陀雅可


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-06-11 16:12:29 評論於
The first round of review was sent out at the end of February and took about two months. Both reviewers requested major revisions. The revisions were completed and responses to reviewers' questions were sent in early May. The second round of review was quick, taking less than 20 days. One reviewer was very thorough and raised some more questions, requesting minor revisions. The revised manuscript was resubmitted in early June and accepted about a week later
(0) 讚! | 韦陀雅可

作者: soinger


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2020-06-11 09:41:55 評論於
The article was submitted at the end of February. It took about two months for the first review. There were two reviewers, who required major revisions. I revised the article in the early May and replied the questions of the reviewers. The second review was fast, which took less than 20 days. One reviewer was very careful, who raised some questions again, and I was required to make minor revisions. I revised the article and responded the questions, and resubmitted it in the early June. It was accepted in about a week.

(2) 讚! | soinger

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2014-12-17 08:42:39 評論於
I only submitted once, in April, and received revisions a month later. It took me a long time to make the revisions myself, so I didn't return the manuscript to the editor-in-chief until November, and it was promptly accepted for a second review. I conducted clinical research on genetic pharmacology, with two peer reviewers - one presumably a physician from the United States and the other presumably a researcher from a non-English speaking country. Their different perspectives led to divergent opinions, but ultimately the editor-in-chief decided to accept my article. In general, all SCI journals have language requirements, and it is advisable to have a native speaker edit the language, as poor language skills can give the impression of low article quality. Many people in English-speaking countries may therefore dismiss an article overall. This was the impression I received from my first peer reviewer. As for content, regardless of the type of research - whether basic or clinical - it is essential to explain the practical significance of the research, such as its implications for future treatment strategies or healthcare regulations. The editor-in-chief particularly favors articles with practical significance. In fact, there are many aspects of my own article that I am not satisfied with, particularly the discussion section, which I wrote in too much detail and consequently reduced the readability of the article. I wanted to share my experience and encourage others
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [PSYCHOPHARMACOLOGY] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*